Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial
Anna Li, Hua‐Jun Chen, Jin‐Ji Yang
Topics & Concepts
OsimertinibMedicineOncologyInternal medicineClinical endpointTolerabilityLung cancerT790MEpidermal growth factor receptorProgression-free survivalCohortGefitinibRandomized controlled trialCancerErlotinibAdverse effectChemotherapyLung Cancer Treatments and MutationsFibroblast Growth Factor ResearchLung Cancer Research Studies